Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

206 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence.
Brown TA 2nd, Mittendorf EA, Hale DF, Myers JW 3rd, Peace KM, Jackson DO, Greene JM, Vreeland TJ, Clifton GT, Ardavanis A, Litton JK, Shumway NM, Symanowski J, Murray JL, Ponniah S, Anastasopoulou EA, Pistamaltzian NF, Baxevanis CN, Perez SA, Papamichail M, Peoples GE. Brown TA 2nd, et al. Among authors: papamichail m. Breast Cancer Res Treat. 2020 Jun;181(2):391-401. doi: 10.1007/s10549-020-05638-x. Epub 2020 Apr 22. Breast Cancer Res Treat. 2020. PMID: 32323103 Free PMC article. Clinical Trial.
A new era in anticancer peptide vaccines.
Perez SA, von Hofe E, Kallinteris NL, Gritzapis AD, Peoples GE, Papamichail M, Baxevanis CN. Perez SA, et al. Among authors: papamichail m. Cancer. 2010 May 1;116(9):2071-80. doi: 10.1002/cncr.24988. Cancer. 2010. PMID: 20187092 Free article. Review.
AE37: a novel T-cell-eliciting vaccine for breast cancer.
Sears AK, Perez SA, Clifton GT, Benavides LC, Gates JD, Clive KS, Holmes JP, Shumway NM, Van Echo DC, Carmichael MG, Ponniah S, Baxevanis CN, Mittendorf EA, Papamichail M, Peoples GE. Sears AK, et al. Among authors: papamichail m. Expert Opin Biol Ther. 2011 Nov;11(11):1543-50. doi: 10.1517/14712598.2011.616889. Epub 2011 Sep 6. Expert Opin Biol Ther. 2011. PMID: 21895539 Review.
Immunologic biomarkers in prostate cancer: the AE37 paradigm.
Baxevanis CN, Papamichail M, Perez SA. Baxevanis CN, et al. Among authors: papamichail m. Hum Vaccin Immunother. 2014;10(5):1244-7. doi: 10.4161/hv.28032. Epub 2014 Feb 19. Hum Vaccin Immunother. 2014. PMID: 24552987 Free PMC article.
Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence.
Mittendorf EA, Ardavanis A, Litton JK, Shumway NM, Hale DF, Murray JL, Perez SA, Ponniah S, Baxevanis CN, Papamichail M, Peoples GE. Mittendorf EA, et al. Among authors: papamichail m. Oncotarget. 2016 Oct 4;7(40):66192-66201. doi: 10.18632/oncotarget.11751. Oncotarget. 2016. PMID: 27589688 Free PMC article. Clinical Trial.
Effects of HLA status and HER2 status on outcomes in breast cancer patients at risk for recurrence - Implications for vaccine trial design.
Jackson DO, Trappey FA, Clifton GT, Vreeland TJ, Peace KM, Hale DF, Litton JK, Murray JL, Perez SA, Papamichail M, Mittendorf EA, Peoples GE. Jackson DO, et al. Among authors: papamichail m. Clin Immunol. 2018 Oct;195:28-35. doi: 10.1016/j.clim.2018.06.008. Epub 2018 Jul 17. Clin Immunol. 2018. PMID: 30025819 Clinical Trial.
Immunogenic HER-2/neu peptides as tumor vaccines.
Baxevanis CN, Sotiriadou NN, Gritzapis AD, Sotiropoulou PA, Perez SA, Cacoullos NT, Papamichail M. Baxevanis CN, et al. Among authors: papamichail m. Cancer Immunol Immunother. 2006 Jan;55(1):85-95. doi: 10.1007/s00262-005-0692-3. Epub 2005 Oct 27. Cancer Immunol Immunother. 2006. PMID: 15948002 Free PMC article. Review.
206 results